Rheumatology 2003; 42: 200-213
© 2003 British Society for Rheumatology
Review |
Central nervous system involvement in the antiphospholipid (Hughes) syndrome
1 Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London, UK and
2 Rheumatology Department, Reina Sofia University Hospital, Cordoba, Spain
The antiphospholipid (Hughes) syndrome (APS) is characterized by arterial and/or venous thrombosis and pregnancy morbidity in the presence of anticardiolipin antibodies and/or lupus anticoagulant. APS can occur either as a primary disorder or secondary to a connective tissue disease, most frequently systemic lupus erythematosus. Central nervous system (CNS) involvement is one of the most prominent clinical manifestations of APS, and includes arterial and venous thrombotic events, psychiatric features and a variety of other non-thrombotic neurological syndromes. In this review we focus on the common and some of the less common CNS manifestations that have been reported in association with antiphospholipid antibodies.
Correspondence to: M. A. Khamashta, Lupus Research Unit, The Rayne Institute, St Thomas' Hospital, London SE1 7EH, UK. E-mail: munther.khamashta{at}kcl.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D Shprecher, T Frech, S Chin, R Eskandari, and J Steffens Progressive multifocal leucoencephalopathy associated with lupus and methotrexate overdose Lupus, November 1, 2008; 17(11): 1029 - 1032. [Abstract] [PDF]
|
|
|
|
 |
|
 H. Raza, S. A. Epstein, M. Pao, and D. L. Rosenstein Mania: Psychiatric Manifestations of the Antiphospholipid Syndrome Psychosomatics, September 1, 2008; 49(5): 438 - 441. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Christodoulou, S. Sangle, and D. P. D'Cruz Vasculopathy and arterial stenotic lesions in the antiphospholipid syndrome Rheumatology, June 1, 2007; 46(6): 907 - 910. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Parikh, K. Shifteh, M.L. Lipton, J.A. Bello, and A.L. Brook Deep Brain Reversible Encephalopathy: Association with Secondary Antiphospholipid Antibody Syndrome AJNR Am. J. Neuroradiol., January 1, 2007; 28(1): 76 - 78. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Tektonidou, N. Varsou, G. Kotoulas, A. Antoniou, and H. M. Moutsopoulos Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med, November 13, 2006; 166(20): 2278 - 2284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Paran, J Chapman, A D Korczyn, O Elkayam, O Hilkevich, G B Groozman, D Levartovsky, I Litinsky, D Caspi, Y Segev, et al. Evoked potential studies in the antiphospholipid syndrome: differential diagnosis from multiple sclerosis Ann Rheum Dis, April 1, 2006; 65(4): 525 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wong, S. Sangle, W. Jan, G. R. V. Hughes, and D. P. D'Cruz Intracerebral arterial stenosis with neurological events associated with antiphospholipid syndrome Rheumatology, July 1, 2005; 44(7): 948 - 949. [Full Text] [PDF]
|
|
|
|
|
|
I Delevaux, M Andre, I Marroun, D Lamaison, J-C Piette, and O Aumaitre Intractable hiccup as the initial presenting feature of systemic lupus erythematosus Lupus, May 1, 2005; 14(5): 406 - 408. [Abstract] [PDF]
|
|
|
|
|
|
S. Ferreira, D. P. D'Cruz, and G. R. V. Hughes Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology, April 1, 2005; 44(4): 434 - 442. [Abstract] [Full Text] [PDF]
|
|